Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer
Status:
COMPLETED
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, open-label, single-arm study evaluating the efficacy and safety of combined treatment of Inosine with chemotherapy in mTNBC (triple negative breast cancer) patients who progressed during previous chemotherapy.